Immunopathology & Immunotherapy

• Yukinori Okada,
• Di Wu,
• Gosia Trynka,
• Towfique Raj,
• Chikashi Terao,
• Katsunori Ikari,
• Yuta Kochi,
• Koichiro Ohmura,
• Akari Suzuki,
• Shinji Yoshida,
• Robert R. Graham,
• Arun Manoharan,
• Ward Ortmann,
• Tushar Bhangale,
• Joshua C. Denny,
• Robert J. Carroll,
• Anne E. Eyler,
• Jeffrey D. Greenberg,
• Joel M. Kremer,
• Dimitrios A. Pappas,
• Lei Jiang,
• Jian Yin,
• Lingying Ye,
• Ding-Feng Su,
• Jian Yang
• et al.

Nature (2013) doi:10.1038/nature12873

Link to a spanish newspaper (El Mundo Salud) summary: 

http://www.elmundo.es/salud/2013/12/24/52b88f9122601dac238b4588.html?goback=%2Egde_1789669_member_5826671948721057795#%21

Including Immunology (pathology and therapies) topics:

• 29 TYpE 2 DiAbETES MElliTUS | A central role of the gut in glucose homeostasis; Geltrude Mingrone and Lidia Castagneto-Gissey
• 30 METAbOliSM | The gut microbiota manages host metabolism; Patrice D. Cani
• 35 hEpATiTiS C | HCV causes systemic disorders that can be cured; Francesco Negro
• 37 fAECAl MiCRObiOTA TRANSplANTATiON | Developing human gut microbiota as a class of therapeutics; Alexander Khoruts
• 38 COEliAC DiSEASE | New insights in dietary-gluten-induced autoimmunity; Katri Kaukinen and Markku Mäki
• 42 ibD | Enriching the therapeutic armamentarium for IBD;  Silvio Danese and Laurent Peyrin-Biroulet
• 51 TRANSplANTATiON iMMUNOlOgY | New approaches to diagnosis of rejection; Nicholas A. Zwang and Laurence A. Turka
• 65 MUlTiplE SClEROSiS | Novel triggers, treatment targets and brain atrophy measures; Xavier Montalban and Mar Tintoré
• 71 SYSTEMiC lUpUS ERYThEMATOSUS | Taking a closer look at biologic therapy for SLE; David A. Isenberg and Anisur Rahman
• 72 EpigENETiCS | DNA methylation and miRNA—key roles in systemic autoimmunity; Bruce C. Richardson and Dipak R. Patel
• 74 RhEUMATOiD ARThRiTiS | Translational medicine in RA—time for change; Pierre Miossec

Volume 12, Issue 11, September 2013, Pages 1076–1084

The lungs are frequently involved in Connective Tissue Diseases (CTDs). Interstitial lung disease (ILD) is one of the most common pleuropulmonary manifestations that affects prognosis significantly. In practice, rheumatologists and other physicians tend to underestimate the impact of CTD-ILDs and diagnose respiratory impairment when it has reached an irreversible fibrotic stage. Early investigation, through clinical evidence, imaging and – in certain cases – lung biopsy, is therefore warranted in order to detect a possible ILD at a reversible initial inflammatory stage. In this review, we focus on lung injury during CTDs, with particular attention to ILDs, and examine their prevalence, clinical manifestations and histological patterns, as well as therapeutic approaches and known complications till date. Although several therapeutic agents have been approved, the best treatment is still not certain and additional trials are required, which demand more knowledge of pulmonary involvement in CTDs.

Our central aim is therefore to document the impact that lung damage has on CTDs. We will mainly focus on Rheumatoid Arthritis (RA), which – unlike other rheumatic disorders – resembles Idiopathic Pulmonary Fibrosis (IPF) in numerous aspects.